Data from the phase 3 double-blind, placebo-controlled SCORED trial, which randomised 10,584 patients with type 2 diabetes, chronic kidney disease, and cardiovascular risk factors to receive sotagliflozin or placebo, were used in the analysis. Laboratory-derived kidney and cardiorenal composites were among the outcomes evaluated.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment